Related Experiment Videos

Structural insights into the activation of P. vivax plasmepsin

Nina Khazanovich Bernstein1, Maia M Cherney, Charles A Yowell

  • 1CIHR Group in Protein Structure and Function, Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2H7.

Insights

Malaria parasites use special enzymes called plasmepsins to break down hemoglobin. Structural studies reveal how inactive plasmepsin zymogens prevent active site formation, offering new anti-malarial drug targets.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Parasitology

Background:

  • Plasmepsins are malarial aspartic proteinases crucial for hemoglobin degradation by Plasmodium species.
  • Plasmepsins are synthesized as inactive zymogens (proplasmepsins) with long N-terminal prosegments.
  • Proplasmepsin activation differs from other aspartic proteinases, suggesting unique inactivation mechanisms.

Purpose of the Study:

  • To determine the crystal structures of plasmepsin and proplasmepsin from Plasmodium vivax.
  • To elucidate the structural basis for the auto-inhibition of proplasmepsins.
  • To provide insights into potential anti-malarial drug targets.

Main Methods:

  • X-ray crystallography was used to determine the three-dimensional structures of P. vivax plasmepsin and proplasmepsin.
  • Comparative structural analysis of proplasmepsin and plasmepsin structures.

Main Results:

  • The crystal structure of P. vivax plasmepsin resembles typical monomeric aspartic proteinases.
  • The P. vivax proplasmepsin structure is similar to P. falciparum proplasmepsin II.
  • Significant conformational changes, including N-terminal refolding and domain reorientation, distort the active site in proplasmepsin, preventing its function.

Conclusions:

  • The auto-inhibition mechanism of proplasmepsins involves an incompletely formed active site, not just substrate access blocking.
  • This structural feature is likely conserved across related proplasmepsins.
  • Understanding these structures provides a basis for designing novel anti-malarial drugs targeting plasmepsins.

Related Concept Videos